tirzepatide injection spots Best Place for Injection: FDA-Approved Sites Doctor Explains How to Dose

It is the first oral small molecule GLP-1 drug to successfully complete phase 3 trials, producing average weight losses of 8% after 40 weeks, and 12% at 72 weeks

These variations don't predict toxicity alone but collectively inform personalized dosing guidance and risk stratification that providers should consider during clinical assessment

Some studies comparing tirzepatide and semaglutide over 72 weeks found that tirzepatide was more effective in reducing body weight and waist circumference

Larsen PJ, Tang-Christensen M, Holst JJ, Orskov C

Your actual cost depends on your deductible status, coinsurance percentage, and whether you have reached your out-of-pocket maximum